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maintenance treatment on the overall sur-
vival of patients with follicular lymphoma, 
previously we performed a systematic 
review and meta-analysis (11) of five ran-
domized controlled trials conducted 
between the years 1998 and 2004 in which 
985 follicular lymphoma patients were ran-
domly assigned to rituximab maintenance 
treatment or to no maintenance (observa-
tion or rituximab at progression). Induction 
therapy consisted of rituximab or chemo-
therapy or a combination of rituximab and 
chemotherapy. Results demonstrated a sta-
tistically significant survival benefit for 
patients with refractory or relapsed (ie, 
previously treated) follicular lymphoma 
who received rituximab maintenance treat-
ment (pooled hazard ratio [HR] of death = 
0.58, 95% CI = 0.42 to 0.79) but not for 
patients after first-line induction therapy 
(pooled HR of death = 0.68, 95% CI = 0.37 
to 1.25). Since our previous publication 
(11), the trials included in the systematic 
review and meta-analysis have published 
updated results, and in addition, new clin-
ical trials have been completed. In this 
study, we report an updated systematic 
review and meta-analysis integrating these 
new results.
The Cochrane Collaboration policy 
requires all systematic reviews to be 
updated within 2 years (12). Because the 
literature search for this review was done in 
June 2007, we decided to update it in 
December 2010. A search for randomized 
controlled trials was performed as described 
previously (11). We searched The 
Cochrane Central Register of Controlled 
Trials, published in The Cochrane Library 
(issue 4, 2010); PubMed (1966 to December 
2010); EMBASE (1974 to June 2007); 
LILACS (1982 to December 2010); the 
database of clinical trials in hematologic 
malignancies (www.hematology-studies.
org); Conference Proceedings of the 
American Society of Hematology (1995 to 
2010), Conference Proceedings of the 
American Society of Clinical Oncology 
Annual Meeting (1995 to 2010), and 
Proceedings of the European Hematology 
Association; and databases of ongoing and 
unpublished trials (http://www.controlled-
trials.com/, http://www.clinicaltrials.gov/
ct, http://clinicaltrials.nci.nih.gov/). The 
Follicular lymphoma is a “slow growing” 
B-cell lymphoma. The median age at diag-
nosis is 63 years (1). Most patients are 
diagnosed with advanced stage (Ann Arbor 
stage III or IV) (2) and are followed with-
out chemotherapy until fever, weight loss 
or night sweats (B symptoms), or signs of 
high tumor bulk occur, or the lymphoma 
jeopardizes an organ function (known as 
the Groupe d’Etude des Lymphomes 
Folliculaires [GELF] criteria) (3,4). 
Patients respond well to the initial (first-
line) rituximab–chemotherapy induction 
but typically experience repeated relapses 
and shortening of the time from treatment 
to treatment (4). Survival of patients with 
follicular lymphoma is shorter compared 
with a matched cohort from the general 
population, with a median survival of 
approximately 10 years (95% confidence 
interval [CI] = 8 to 12 years) (1,5).
Addition of rituximab to induction 
chemotherapy (rituximab–chemotherapy 
induction) improves survival of patients 
with follicular lymphoma compared with 
induction chemotherapy, but most patients 
are not cured and experience relapse after a 
median of 4 years (95% CI = 3.17 to not 
reached) (6–8). Rituximab maintenance 
treatment after any induction therapy 
improves progression-free survival, but 
evidence of improved overall survival is 
lacking from randomized controlled trials 
(9,10). To evaluate the effect of rituximab 
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0.92) compared with patients in the no maintenance group. Patients with refractory 
or relapsed (ie, previously treated) follicular lymphoma treated with rituximab 
maintenance had improved overall survival (pooled HR of death = 0.72, 95% CI = 0.57 
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standard of care for refractory or relapsed follicular lymphoma.
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terms “follicular” or “indolent” and similar 
terms, and “lymphoma” and similar terms 
were cross-searched with “rituximab” or 
“monoclonal antibodies” and similar terms. 
We contacted the first or corresponding 
author of each included trial to obtain com-
plementary information or information on 
unpublished trials. The primary outcome 
was overall survival. Secondary outcomes 
included progression-free survival [as 
defined in Cheson et al. (13)], quality of 
life, and adverse events: grade 3 or 4 
adverse events ([according to the US 
National Cancer Institute’s Common 
Terminology Criteria for Adverse Events, 
CTCAE, version 3]. If the trials used the 
term grade but did not define the grading 
system, we assumed grading was defined 
according to CTCAE), adverse events re-
quiring discontinuation of therapy, infec-
tions, and severe infections (as defined in 
each trial). In our previous protocol 
designed in 2007, we also planned to ana-
lyze event-free survival, rate of disappear-
ance of B-cell CLL/lymphoma 2 (BCL2) 
protein from biopsy specimen, and response 
duration. We amended the protocol and 
did not include these outcome measures in 
the current meta-analysis.
Subgroup analyses for the primary out-
come were planned according to the type 
of induction therapy (chemotherapy only, 
rituximab only, rituximab combined with 
chemotherapy, any regimen containing 
rituximab), rituximab schedule, treatment 
line, blinding of patients, caregivers, or 
outcome assessors, and adequacy of alloca-
tion concealment and adequacy of sequence 
generation. All subgroup analyses of pro-
gression-free survival (by type of induction 
therapy, type of chemotherapy, treatment 
line) were not planned a priori in the 
protocol.
Hazard ratios and 95% confidence 
intervals for time-to-event outcomes were 
estimated (14,15) and pooled using inverse 
variance method in a fixed effect model. 
A hazard ratio less than 1.0 was in favor of 
rituximab maintenance treatment. Risk 
ratios (RRs) and 95% confidence intervals 
for dichotomous data were estimated and 
pooled using a fixed effect model (the 
Mantel–Haenszel method) (16). For the 
primary outcome, we performed a sensi-
tivity analysis by repeating the analysis 
using a random effects model [the 
DerSimonian and Laird method; (17)]. We 
assessed heterogeneity of trial results by 
the x2 test of heterogeneity and the I2 statis-
tic of inconsistency. Statistically significant 
heterogeneity was defined as P less than .1 
or an I2 statistic greater than 50% (18). All 
statistical tests were done by Review 
Manager (RevMan) version 5.1 
(Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 
2011) and were two-sided.
The literature search identified 873 ref-
erences, of which 64 references were con-
sidered potentially relevant (8–10,19–79), 
and 50 references were excluded (19–68). 
Ten trials fulfilled inclusion criteria (8–
10,69–79), including five new trials 
(8,69,73,76–78) and three updated data of 
trials (71,72,75) included in our previous 
report (11). One trial did not report rele-
vant clinical data (78). Two of the publica-
tions (71,79) reported the outcomes of 
different subsets of patients from the same 
trial.
The trial and patient characteristics are 
shown in Tables 1 and 2. Patients were 
eligible for trial entry if they had at least 
partial response (8,10,73–76) or at least 
stable disease (9,69–72,79) after induction 
therapy. In one trial (70), patients in the no 
maintenance group were eligible for ritux-
imab upon progression of follicular lym-
phoma; in other trials, patients in the 
control group were observed without ritux-
imab treatment.
Patients included in one trial (69) ful-
filled GELF criteria for deferred treatment 
(3). In the original trial (69), patients were 
randomly assigned to one of three groups—
observation, rituximab induction, or ritux-
imab induction and maintenance. To avoid 
overestimation of the effect of rituximab 
maintenance, we chose to compare patients 
who received rituximab induction and 
maintenance with those who received 
rituximab induction only and not with 
those in the observation group. Thus, in 
this meta-analysis, patients who received 
only rituximab induction and no mainte-
nance were used as the control group.
Nine trials performed between 1998 
and 2009 (2586 patients) were eligible for 
the meta-analysis of overall survival (8–
10,69–77,79). Patients treated with ritux-
imab maintenance had statistically 
significantly better overall survival com-
pared with patients in the no maintenance 
group (pooled HR of death = 0.76, 95% 
CI = 0.62 to 0.92) (Figure 1). No statisti-
cally significant heterogeneity among the 
trials was observed for overall survival 
(Pheterogeneity = .0). The funnel plot of the pri-
CONTEXTS AND CAVEATS
Prior knowledge
Most follicular lymphoma patients respond 
to induction chemotherapy but experience 
repeated relapses. A previously conducted 
systematic review and meta-analysis of five 
randomized controlled trials that compared 
rituximab maintenance treatment with no 
maintenance showed survival benefit for 
patients with refractory or relapsed (previ-
ously treated) follicular lymphoma who 
received rituximab maintenance, but not 
untreated patients.
Study design
An updated systematic review and meta-
analysis was conducted by including nine 
randomized trials, and patients treated with 
rituximab maintenance were compared 
with no maintenance group.
Contribution
Patients treated with rituximab mainte-
nance showed statistically significantly 
better overall and progression-free survival 
compared with patients in the no mainte-
nance group. Subgroup analysis of overall 
survival showed that patients with refrac-
tory or relapsed follicular lymphoma had a 
clear survival benefit with rituximab main-
tenance treatment, but previously un-
treated patients did not have a statistically 
significant survival benefit. A higher rate of 
infection-related adverse events was noted 
in the rituximab maintenance group.
Implications
The updated meta-analysis confirms the 
results of the former meta-analysis. 
Rituximab maintenance improves survival 
in previously treated patients, and although 
untreated patients show progression-free 
survival benefit, they do not show overall 
survival benefit. The higher rate of infection-
related adverse events in the rituximab 
maintenance group needs to be considered 
while treating the patients.
Limitations
An increased chance of false-positive 
results is possible because of repeated 
meta-analysis.
From the Editors
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mary outcome did not support a publica-
tion bias (data not shown).
A subgroup analysis of overall survival 
showed that patients with refractory or 
relapsed (ie, previously treated) follicular 
lymphoma (909 patients) (9,10,70,72–75) 
had a clear survival benefit with rituximab 
maintenance treatment (pooled HR of 
death = 0.72, 95% CI = 0.57 to 0.91), 
whereas previously untreated patients 
(maintenance after first-line induction 
therapy) (1650 patients) (8,9,69,71,72,79) 
did not (pooled HR of death = 0.86, 95% 
CI = 0.60 to 1.25) (Figure 1, and 
Supplementary Table 1, available online). 
Chemotherapy regimen and the schedule 
of rituximab maintenance had no statisti-
cally significant effect on outcome 
(Supplementary Table 1, available online). 
Three trials included patients whose induc-
tion therapy consisted of single-agent 
rituximab with no chemotherapy 
(9,69,70,72). Analysis of these trials (516 
patients) showed that rituximab mainte-
nance treatment had no statistically signifi-
cant effect on overall survival compared 
with no maintenance therapy (pooled HR 
of death = 0.76, 95% CI = 0.53 to 1.01). 
The sensitivity analysis by quality of alloca-
tion concealment (adequate or not 
reported) did not show an effect of quality 
of concealment on the outcomes 
(Supplementary Table 1, available online).
In most of the included trials, progression- 
free survival improved with rituximab 
maintenance treatment compared with no 
maintenance (8-10,69–76). The pooled haz-
ard ratios from nine trials (2550 patients) 
(8,10,69–73,75,76,79) showed a statistically 
significantly improved progression-free 
survival (pooled HR of disease progression 
or death = 0.54, 95% CI = 0.48 to 0.60). 
This effect was consistent both in previ-
ously untreated patients (1650 patients) 
(8–10,69,71,79) (pooled HR of disease pro-
gression or death = 0.52, 95% CI = 0.44 to 
0.61) and in those with refractory or 
relapsed lymphoma (maintenance ritux-
imab after two or more inductions) (909 
patients) (9,10,70,72,73,75) (pooled HR of 
disease progression or death = 0.60, 95% 
CI = 0.49 to 0.72), following different in-
duction therapies: rituximab alone (516 
patients) (9,69,70,72) (pooled HR of disease 
progression or death = 0.50, 95% CI = 0.39 
to 0.65); chemotherapy alone (297 patients) 
(71,79) (pooled HR of disease progression Ta
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or death = 0.49, 95% CI = 0.37 to 0.66); 
and rituximab–chemotherapy (1352 
patients) (8,74,75) (pooled HR 
of disease progression or death = 0.58, 
95% CI = 0.48 to 0.70). The benefit in 
progression-free survival was observed in 
patients treated with different chemotherapy 
regimens (with or without rituximab); in 
patients treated with cyclophosphamide, 
vincristine, adriamycin, and prednisone, 
the pooled hazard ratio for disease progres-
sion or death was 0.53 (95% CI = 0.44 to 
0.64), with cyclophosphamide, vincristine, 
and prednisone the pooled hazard ratio 
of disease progression or death was 0.50 
(95% CI = 0.38 to 0.66), with fludarabine- 
containing regimen the hazard ratio of 
disease progression or death was 0.58 (95% 
CI = 0.40 to 0.84).
In two trials, the quality of life was 
assessed and censored at the time of pro-
gression (8,77). As shown in each of these 
trials, rituximab maintenance did not 
impair the quality of life. We could not 
analyze quality of life in the meta-analysis 
because of the scarcity of data.
Rituximab maintenance treatment was 
associated with a higher rate of grade 3 or 
4 adverse events compared with the no 
maintenance (1598 patients) (8–10,69) (RR = 
1.60, 95% CI = 1.29 to 1.99). Rituximab 
maintenance group was also associated 
with a higher rate of infections compared 
with no maintenance (1656 patients) (8–
10,74,75) (pooled RR = 1.67, 95% CI = 
1.40 to 2.00). When only grade 3 or 4 
infection–related adverse events were in-
cluded in the analysis (1656 patients) 
(8,10,72,74,75), rituximab maintenance was 
associated with an even higher rate com-
pared with no maintenance (pooled RR = 
3.55, 95% CI = 1.88 to 6.69). A higher rate 
of adverse events requiring discontinuation 
of rituximab (1433 patients) (8,70,74) was 
associated with rituximab maintenance 
group compared with no maintenance 
group (pooled RR = 2.72, 95% CI = 1.30 to 
5.68).
Rituximab maintenance improved over-
all survival and disease control in patients 
with follicular lymphoma who responded 
to induction therapy (P = .006). The accu-
mulating data from new and updated clin-
ical trials strengthen the results of our 
former meta-analysis (11). The large 
sample size and longer follow-up period in 
some of the trials consolidate the results of Ta
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Figure 1. Pooled hazard ratios (HRs) of overall survival of patients with 
follicular lymphoma after first induction and refractory or relapsed 
disease. Nine trials were included in meta-analysis; no death occurred 
in one trial (76), and it did not contribute to the pooled analysis. Black 
squares represent the point estimate (HR), their sizes represent their 
weight in the pooled analysis, and the horizontal bars represent the 
95% confidence intervals (CIs), unidirectional arrows represent a 
limit of the CI that is higher than 10, and the center of the black 
diamonds represent the pooled point estimate, and their horizontal 
axis represents the pooled 95% CI. The black diamond at the bottom 
represents the pooled point estimate. MR = maintenance therapy with 
rituximab. SE = standard error.
HR (95% CI) HR (95% CI)
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(0.30 to 1.20)
(0.35 to 3.34)
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(0.57 to 0.91)
(0.62 to 0.92)
No deaths
occured
No deaths
occured
this study. Although a clear survival benefit 
of rituximab maintenance was observed 
only for patients with relapsed or refractory 
follicular lymphoma, the magnitude of 
progression-free survival benefit was sim-
ilar after first induction as well as after two 
or more inductions, and was consistent in 
different subgroups of patients.
A limitation of repeating the meta-
analysis is the increased chance of false-
positive results. The reported point 
estimates and confidence intervals were not 
adjusted for repeated analyses.
The highly statistically significant 
progression-free survival benefit of ritux-
imab maintenance was not translated to 
a statistically significant overall survival 
benefit after first induction treatment in 
patients with follicular lymphoma. This 
may be because a longer follow-up is 
required to demonstrate a statistically sig-
nificant difference in survival of patients in 
first remission whose estimated survival is 
in the range of decades (1,80), as opposed 
to few years in patients in second or third 
remission. Alternatively, disease progres-
sion per se may not always be a clinically 
meaningful event, and second-line treat-
ment may be efficient in these patients. 
Thus, for patients with relapsed follicular 
lymphoma who responded to induction 
therapy, rituximab maintenance should be 
considered the standard of care. For first-
line, treatment options should be discussed 
with patients in light of the statistically 
significant prolongation of progression-
free survival vs increased rate of infections.
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